CMC Biologics, a contract biologics manufacturer, will supply bulk drug intermediate for CSL Behring'sr ecently FDA-approved product, Afstyla (antihemophilic factor [recombinant], single chain), a long-lasting recombinant factor VIII single-chain therapy to treat adults and children with hemophilia A.

CMC Biologics has an agreement with CSL Behring for the manufacture of the first intermediate of recombinant factor VIII single-chain drug substance. CMC Biologics' facility in Copenhagen, Denmark was inspected by the US Food and Drug Administration as part of the approval for the commercial manufacture of Afstyla.

Source: CMC Biologics